Tyra Biosciences (NASDAQ:TYRA) Price Target Increased to $32.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its target price boosted by investment analysts at HC Wainwright from $30.00 to $32.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 45.92% from the stock’s previous close.

A number of other brokerages also recently issued reports on TYRA. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price objective for the company. Oppenheimer raised their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Friday. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $22.00 to $31.00 in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $31.40.

Tyra Biosciences Stock Performance

TYRA stock opened at $21.93 on Monday. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -12.98 and a beta of 1.01. The business’s 50-day moving average is $22.89 and its two-hundred day moving average is $19.87. Tyra Biosciences has a fifty-two week low of $10.38 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. Equities analysts predict that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $27.90, for a total transaction of $532,443.60. Following the sale, the chief executive officer now owns 1,355,927 shares in the company, valued at $37,830,363.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 61,403 shares of company stock worth $1,582,774. 15.40% of the stock is owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. HighVista Strategies LLC bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at about $257,000. SG Americas Securities LLC bought a new position in Tyra Biosciences during the third quarter valued at approximately $311,000. Rhumbline Advisers grew its holdings in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after acquiring an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $977,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.